For Co-Infections, Viruses and comprehensive testing for Lyme disease.
The broad range of test from the specialist BCA-Lab formerly know as InfectoLab is also supported with Highly Accurate LTT options on most tests. Clear readable reports, prompt processing. competitive pricing.
For full details of different testing services Review BCA Lab Tests
BCA-lab is a medical services provider and a division of BCA-clinic Betriebs GmbH & Co. KG (bca-clinic.de), located in Augsburg. Established in 2006, the laboratory provides diagnostic tests and conducts research into a wide range of vector-borne diseases.
The laboratory is dedicated to continuously adjusting diagnostic requirements, monitoring treatment and performing state-of-the-art research. They provide a close relationship between patients’ treatment and the laboratory, which is very beneficial to customers.
Unlike other laboratory providers, BCA Laboratory is headed by an expert in tickborne infections treatment Dr Carsten Nicolaus, which is why Regenerus Laboratories have chosen them over other potential suppliers, with their integrity, quality and knowledge.
Advanced testing capability
The EliSpot is a tried, tested and reliable method that we have been using to detect infections of Borrelia and its co-infections on a cellular level for several years. The first generation of enzymatic EliSpots determines the quantity of CD3 and CD57-NK-cells and provides important information about the infection. We have now developed this test even further.
The new EliSpot, LymeSpot Revised, delivers detailed information about the activity of the infection. This test is better at determining whether we are dealing with an active (specific effector-cells) or a latent (specific memory-cells) infection. It will now be possible to evaluate whether the problem lies with a patient’s infection, an inflammation or their autoimmune processes. EliSpot is based on the production of γ-interferon, whereas LymeSpot also detects cytokine IL-2.
Using LymeSpot’s ‘traffic light’ principle, an active infection (mainly the effector-cells) will be indicated by green, which shows that the infection needs to be treated. If the relationship between y-interferon
and interleukin-2 is inverted, the disease is more likely to be at a latent stage. This is indicated by a red colouration of the cells (mainly memory-cells) and in this case an anti-infective treatment would
not be applicable. If the memory cells and effector-cells are both present, indicated by red and green together, then both the infection and the inflammation are still present. In this case, the best course
of therapy will be decided based upon the clinical profile of the patient.
This additional differentiation allows us to make much more clear and informed decisions on how to approach a patient’s treatment.